An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis

Abstract

Therapeutic targeting of metastatic breast cancer still remains a challenge as the tumor cells are highly heterogenous and exploit multiple pathways for their growth and metastatic spread that cannot always be targeted by a single-agent monotherapy regimen. Therefore, a rational approach through simultaneous targeting of several pathways may provide a better anti-cancer therapeutic effect. We tested this hypothesis using a combination of two nutraceutical agents S-adenosylmethionine (SAM) and Vitamin D (Vit. D) prohormone [25-hydroxyvitamin D; ‘25(OH)D’] that are individually known to exert distinct changes in the expression of genes involved in tumor growth and metastasis. Our results show that both SAM and 25(OH)D monotherapy significantly reduced proliferation and clonogenic survival of a panel of breast cancer cell lines in vitro and inhibited tumor growth, lung metastasis, and breast tumor cell colonization to the skeleton in vivo. However, these effects were significantly more pronounced in the combination setting. RNA-Sequencing revealed that the transcriptomic footprint on key cancer-related signaling pathways is broader in the combination setting than any of the monotherapies. Furthermore, comparison of the differentially expressed genes from our transcriptome analyses with publicly available cancer-related dataset demonstrated that the combination treatment upregulates genes from immune-related pathways that are otherwise downregulated in bone metastasis in vivo. Since SAM and Vit. D are both approved nutraceuticals with known safety profiles, this combination treatment may serve as a novel strategy to reduce breast cancer-associated morbidity and mortality.

References

[1] Torre LA et al. Global cancer statistics, 2012. CA: Cancer J. Clin., 2015, 65:87-108

[2] Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA: aCancer J. Clin., 2006, 56:37-47

[3] Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer, 2007, 7:684

[4] Davis CD. Vitamin D and cancer: current dilemmas and future research needs–. Am. J. Clin. Nutr., 2008, 88:565S-569S

[5] Rohan T. Epidemiological studies of vitamin D and breast cancer. Nutr. Rev., 2007, 65:S80-S83

[6] Ng K et al. SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol., 2017, 35:3506-3506

[7] Manson JE et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N. Engl. J. Med., 2019, 380:33-44

[8] Mahmood N et al. Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications. Oncotarget, 2018, 9:5169-5183

[9] Şahin M, Şahin E, Gümüşlü S, Erdoğan A, Gültekin M. Inhibition of angiogenesis by S-adenosylmethionine. Biochem. Biophys. Res. Commun., 2011, 408:145-148

[10] Li, T. W. et al. S-Adenosylmethionine and methylthioadenosine inhibit cellular FLICE inhibitory protein expression and induce apoptosis in colon cancer cells. Mol. Pharmacol. 76, 192–200 (2009).

[11] Shukeir N et al. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Br. J. Pharmacol., 2015, 172:2769-2781

[12] Parashar S et al. S‐adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications. Cancer Med., 2015, 4:732-744

[13] Rossdeutscher, L. et al. Chemoprevention activity of 25-hydroxyvitamin D in the MMTV-PyMT mouse model of breast cancer. Cancer Prev. Res. 8, 120–128 (2014).

[14] Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res., 2014, 34:1163-1166

[15] Townsend K et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer Res., 2005, 11:3579-3586

[16] Martin MD et al. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res, 2008, 68:6251-6259

[17] Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411:342

[18] Li J et al. Tumoral vitamin D synthesis by CYP27B1 1-α-hydroxylase delays mammary tumor progression in the PyMT-MMTV mouse model and its action involves NF-κB modulation. Endocrinology, 2016, 157:2204-2216

[19] Rossdeutscher L et al. Chemoprevention activity of 25-hydroxyvitamin D in the MMTV-PyMT mouse model of breast cancer. Cancer Prev. Res., 2015, 8:120-128

[20] Prichard MN, Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res., 1990, 14:181-205

[21] Soica C et al. The synergistic biologic activity of oleanolic and ursolic acids in complex with hydroxypropyl-γ-cyclodextrin. Molecules, 2014, 19:4924-4940

[22] Lin EY et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol., 2003, 163:2113-2126

[23] Leyssens C, Verlinden L, Verstuyf A. Antineoplastic effects of 1,25(OH)₂D3 and its analogs in breast, prostate and colorectal cancer. Endocr. Relat. Cancer, 2013, 20:R31-R47

[24] Shishido S, Delahaye A, Beck A, Nguyen TA. The MMTV-PyVT transgenic mouse as a multistage model for mammary carcinoma and the efficacy of antineoplastic treatment. J. Cancer Ther., 2013, 4:1187

[25] Tauro M et al. Bone-seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth. Mol. Cancer Ther., 2017, 16:494-505

[26] Thiolloy S et al. An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS One, 2012, 7

[27] Bidwell BN et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med., 2012, 18:1224

[28] Wan, Q. et al. BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database 2015, bav019 (2015).

[29] Mahmood N, Rabbani SA. Targeting DNA hypomethylation in malignancy by epigenetic therapies. Adv. Exp. Med. Biol., 2019, 1164:179-196

[30] Cheishvili D, Boureau L, Szyf M. DNA demethylation and invasive cancer: implications for therapeutics. Br. J. Pharmacol., 2015, 172:2705-2715

[31] Mahmood N, Rabbani SA. DNA methylation and breast cancer: mechanistic and therapeutic applications. Trends Cancer Res., 2017, 12:1-18

[32] Rawson JB et al. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients. Nutr. Cancer, 2012, 64:919-928

[33] Tapp HS et al. Nutritional factors and gender influence age‐related DNA methylation in the human rectal mucosa. Aging Cell, 2013, 12:148-155

[34] Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br. J. Cancer, 1987, 55:61-66

[35] Coleman RE. Skeletal complications of malignancy. Cancer, 1997, 80:1588-1594

[36] Singh, G. & Rabbani, S. A. Bone metastasis. New Jersey: Human Press Inc; (2005).

[37] Carney M, Chary T, Bottiglieri T, Reynolds E. The switch mechanism and the bipolar/unipolar dichotomy. Br. J. Psychiatry, 1989, 154:48-51

[38] Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S‐adenosyl‐L‐methionine (SAMe) in humans. Pharmacotherapy, 2004, 24:1501-1507

[39] Martin MD et al. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res., 2008, 68:6251-6259

[40] Zhao Y et al. Overexpression of interferon regulatory factor 7 (IRF7) reduces bone metastasis of prostate cancer cells in mice. Oncol. Res., 2017, 25:511-522

[41] Chiappinelli KB et al. Inhibiting DNA methylation causes an interferon response in cancer via dsrna including endogenous retroviruses. Cell, 2015, 162:974-986

[42] Spektor R, Tippens ND, Mimoso CA, Soloway P. D. methyl-ATAC-seq measures DNA methylation at accessible chromatin. Genome Res., 2019, 29:969-977

[43] Ghosh S et al. TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo. Mol. Cancer Ther., 2019, 18:632-641

[44] Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res., 2010, 12:R56-R56

[45] Cheishvili D et al. Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2ʹ-deoxycytidine-triggered invasiveness. Carcinogenesis, 2014, 35:2436-2446

[46] Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics, 2014, 30:2114-2120

[47] Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods, 2015, 12:357

[48] Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics, 2015, 31:166-169

[49] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15

[50] Kamburov A, Stelzl U, Lehrach H, Herwig R. The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res., 2013, 41:D793-D800

[51] Subramanian A et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA, 2005, 102:15545-15550

[52] Tripathi S et al. Meta-and orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding. Cell Host Microbe, 2015, 18:723-735

Funding

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre)(130410)